Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Clidinium bromide is an anticholinergic and antispasmodic medication used primarily to treat gastrointestinal disorders like peptic ulcers and irritable bowel syndrome by reducing stomach acid and gut spasms.
Name
Clidinium
Raw Name
CLIDINIUM BROMIDE
Category
Other
Salt Form
Bromide
Drug Count
4
Variant Count
19
Last Verified
February 17, 2026
RxCUI
889614, 889616
UNII
MFM6K1XWDK, 91ZQW5JF1Z
About Clidinium
Clidinium bromide is an anticholinergic and antispasmodic medication used primarily to treat gastrointestinal disorders like peptic ulcers and irritable bowel syndrome by reducing stomach acid and gut spasms.
Detailed information about Clidinium
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Clidinium.
Pharmacologically, clidinium belongs to the class of drugs known as antimuscarinics. These agents work by competitively inhibiting the action of acetylcholine at muscarinic receptors located throughout the body, particularly in the smooth muscles of the digestive tract and secretory glands. By blocking these receptors, clidinium helps to reduce the motility (movement) of the gastrointestinal tract and decrease the secretion of gastric acid. The FDA first approved clidinium bromide in the 1960s, and while newer medications have emerged, it remains a valuable tool for patients who do not respond to first-line therapies for irritable bowel syndrome (IBS) or peptic ulcer disease.
To understand how clidinium works, one must first understand the role of the parasympathetic nervous system in digestion. The parasympathetic system, often called the 'rest and digest' system, uses acetylcholine to signal muscles in the gut to contract and glands to produce acid and enzymes. In conditions like irritable bowel syndrome or enterocolitis (inflammation of the digestive tract), these signals can become overactive or disorganized, leading to painful cramping, urgency, and excessive acid production.
At the molecular level, clidinium bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (specifically M1, M2, and M3 subtypes). By binding to these receptors, clidinium prevents acetylcholine from attaching to them. The primary therapeutic effect occurs at the M3 receptors located on the smooth muscle cells of the intestines. When these receptors are blocked, the muscle fibers relax, which reduces the frequency and intensity of spasms. Additionally, clidinium acts on the M1 receptors of the gastric parietal cells (acid-producing cells in the stomach), leading to a moderate reduction in the volume and acidity of gastric secretions. Because it is a quaternary ammonium compound, it carries a positive charge that limits its ability to cross the blood-brain barrier compared to tertiary amines like atropine, theoretically resulting in fewer central nervous system side effects at standard doses.
The movement of clidinium through the body is characterized by its chemical structure as a quaternary amine, which influences its absorption and distribution significantly.
Clidinium is FDA-approved for use as adjunctive therapy in the treatment of several gastrointestinal conditions. 'Adjunctive' means it is used alongside other treatments rather than as a standalone cure. Approved and common off-label uses include:
Clidinium bromide is almost exclusively available in the following form:
While pure clidinium bromide powder exists for compounding, the commercial market is dominated by the combination capsule. Patients should be aware that the presence of chlordiazepoxide adds a sedative component and a risk of dependency that is not present with clidinium alone.
> Important: Only your healthcare provider can determine if Clidinium is right for your specific condition. This information is for educational purposes and does not replace professional medical advice.
The dosage of clidinium must be individualized based on the severity of the symptoms and the patient's response to the medication. Because clidinium is most commonly prescribed as a combination product (e.g., Librax), the dosing reflects the combined effect of the antispasmodic and the sedative.
The safety and effectiveness of clidinium bromide in pediatric patients have not been established through rigorous clinical trials. Due to the potential for anticholinergic toxicity (which can cause high fever, rapid heart rate, and mental status changes in children) and the sedative effects of the chlordiazepoxide component, clidinium is generally NOT recommended for use in children under the age of 18. If a healthcare provider determines it is necessary, they will calculate a highly specific dose based on body weight and monitor the child closely in a clinical setting.
Clidinium is primarily excreted by the kidneys. In patients with significant renal impairment (kidney disease), the drug may accumulate in the body, increasing the risk of side effects. Healthcare providers may reduce the frequency of dosing or the total daily dose for these patients. Monitoring for signs of anticholinergic toxicity (e.g., extreme dry mouth, urinary retention) is essential.
Since the liver is involved in the metabolism of clidinium and its common companion drug, chlordiazepoxide, patients with liver cirrhosis or hepatitis require cautious dosing. Lower starting doses are typically utilized to prevent over-sedation and prolonged drug effects.
Geriatric patients are particularly sensitive to the effects of anticholinergic drugs. In the elderly, clidinium can cause significant confusion, memory loss, and an increased risk of falls. Furthermore, older men with prostatic hypertrophy (enlarged prostate) are at high risk for acute urinary retention. The American Geriatrics Society's Beers Criteria recommends avoiding potent anticholinergics in this population. If used, the dose should be kept at the lowest effective level, often starting with just one capsule twice daily.
To ensure the medication works correctly and to minimize side effects, follow these guidelines:
If you miss a dose of clidinium, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not double the dose to catch up, as this significantly increases the risk of side effects like blurred vision or heart palpitations.
An overdose of clidinium bromide can be serious and requires immediate medical attention. Signs of overdose include:
In case of a suspected overdose, contact your local poison control center or seek emergency medical services immediately. Treatment in a hospital setting may include gastric lavage (stomach pumping), supportive care for breathing and heart rate, and the administration of specific antidotes like physostigmine in severe cases of anticholinergic syndrome.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Because clidinium affects the parasympathetic nervous system throughout the body, side effects are common. Most are related to the 'drying' effect of the drug. Common experiences include:
> Warning: Stop taking Clidinium and call your doctor immediately if you experience any of these serious symptoms.
Prolonged use of clidinium can lead to several chronic issues. Chronic dry mouth can lead to significant periodontal (gum) disease and tooth loss. There is also evidence suggesting that long-term use of potent anticholinergics may be associated with an increased risk of cognitive decline or dementia in older adults. Furthermore, if taken in the combination form with chlordiazepoxide, long-term use can lead to physical and psychological dependence, with severe withdrawal symptoms if the medication is stopped abruptly.
There is no standalone FDA black box warning for clidinium bromide. However, the most common commercial form of this drug is the combination of Clidinium and Chlordiazepoxide.
Chlordiazepoxide carries a Black Box Warning regarding the risks of concomitant use with opioids. The use of benzodiazepines and opioids together may result in profound sedation, respiratory depression (dangerously slow breathing), coma, and death. If you are prescribed this combination, your doctor must monitor you closely and prescribe the lowest effective doses for the shortest possible duration.
Report any unusual symptoms to your healthcare provider immediately. Regular follow-ups are necessary to ensure the medication remains safe and effective for you.
Clidinium is a potent medication that requires careful monitoring. Patients must be aware that it can impair both physical and mental abilities. Because it reduces the body's ability to sweat, patients taking clidinium are at a significantly higher risk of heat exhaustion and heat stroke. Avoid strenuous exercise or prolonged exposure to heat while taking this medication. Additionally, clidinium can cause significant drowsiness, which is exacerbated if taken with other sedatives or alcohol.
As noted previously, clidinium bromide itself does not have a black box warning. However, the combination product containing chlordiazepoxide has a Black Box Warning regarding the risk of serious injury or death when used with opioid pain medications. Patients should never combine these medications unless specifically directed and monitored by a physician. There is also a warning regarding the risk of abuse, misuse, and addiction associated with the benzodiazepine component of the combination product.
If you are taking clidinium long-term, your healthcare provider may require periodic check-ups, including:
Clidinium may cause blurred vision, dizziness, and drowsiness. These effects are significantly increased if the drug is taken in combination with chlordiazepoxide. Do not drive, operate heavy machinery, or engage in potentially dangerous activities until you know exactly how this medication affects you. Your reaction time and clarity of thought may be impaired even if you do not 'feel' sedated.
Alcohol must be avoided while taking clidinium. Alcohol increases the sedative effects of the drug, leading to extreme drowsiness and impaired coordination. If taking the combination product with chlordiazepoxide, mixing with alcohol can lead to dangerous respiratory depression (slowed breathing) and increased risk of overdose.
Do not stop taking clidinium suddenly if you have been taking it for a long period, especially the combination form. Abruptly stopping a benzodiazepine-containing product can lead to withdrawal symptoms such as tremors, sweating, muscle cramps, vomiting, and even seizures. Your doctor will provide a tapering schedule to slowly reduce the dose over several weeks.
> Important: Discuss all your medical conditions with your healthcare provider before starting Clidinium.
Certain medications should never be taken with clidinium due to the risk of severe, life-threatening interactions:
Clidinium does not typically interfere with common blood chemistry or hematology tests. However, if you are undergoing a Gastric Secretion Test, clidinium must be stopped at least 24-48 hours before the test, as it will artificially suppress acid production and lead to inaccurate results.
For each major interaction, the mechanism usually involves either pharmacodynamic synergy (two drugs doing the same thing to a dangerous degree) or altered absorption (one drug changing how the other is taken up by the body). Management usually involves dose adjustment, timing changes, or selecting an alternative medication.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Clidinium bromide must NEVER be used in patients with the following conditions, as the risks far outweigh any potential benefits:
In these conditions, clidinium should only be used if the healthcare provider determines the benefit is essential and can monitor the patient closely:
Patients who have demonstrated a severe allergy or hypersensitivity to other quaternary ammonium anticholinergics (such as glycopyrrolate or ipratropium) should avoid clidinium, as there is a risk of cross-reactivity. Symptoms of an allergic reaction include skin rash, itching, and in severe cases, swelling of the throat or difficulty breathing.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Clidinium.
Clidinium bromide is generally classified in FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, or there are no adequate and well-controlled studies in humans. However, the combination product (clidinium/chlordiazepoxide) is often classified in Category D because chlordiazepoxide (a benzodiazepine) has been associated with an increased risk of congenital malformations (birth defects) when taken during the first trimester.
Use of clidinium during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. If you become pregnant while taking this medication, contact your doctor immediately. It is generally advised to avoid this medication during the first trimester due to the risk of cleft lip or palate associated with benzodiazepines.
It is not known with certainty whether clidinium bromide is excreted in human milk. However, anticholinergic drugs in general may suppress lactation (milk production) by inhibiting the hormone prolactin. Additionally, the chlordiazepoxide component of combination products does pass into breast milk and can cause sedation and feeding difficulties in the nursing infant. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug.
As previously noted, clidinium is not approved for use in children. Pediatric patients are more susceptible to the toxic effects of anticholinergics, including 'anticholinergic psychosis' (hallucinations and confusion) and severe hyperthermia (high body temperature). If a child accidentally ingests clidinium, seek emergency medical care immediately.
Patients over the age of 65 are at the highest risk for adverse effects. The aging brain is more sensitive to acetylcholine blockade, leading to a high incidence of drug-induced delirium. Furthermore, older adults often have decreased kidney and liver function, leading to higher drug concentrations. The risk of falls and subsequent hip fractures is a major concern in this population. Healthcare providers are encouraged to use alternative treatments for GI distress in the elderly whenever possible.
In patients with a Glomerular Filtration Rate (GFR) below 30 mL/min, the clearance of clidinium is significantly reduced. While there are no specific 'dialysis' dosing guidelines, it is generally assumed that clidinium is not efficiently removed by hemodialysis due to its tissue distribution. Doses should be spaced further apart in patients with chronic kidney disease.
For patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), the starting dose should be reduced by 50%. In severe hepatic impairment (Child-Pugh Class C), the drug should be avoided if possible, as the risk of hepatic encephalopathy (brain dysfunction due to liver failure) can be exacerbated by the sedative effects of the combination medication.
> Important: Special populations require individualized medical assessment and frequent monitoring by a healthcare professional.
Clidinium bromide is a competitive inhibitor of acetylcholine at the postganglionic parasympathetic receptor sites. These receptors, known as muscarinic receptors, are found in the smooth muscle of the gastrointestinal tract, the secretory glands, and the heart. By occupying these receptor sites, clidinium prevents acetylcholine from triggering the 'G-protein' signaling cascade that normally leads to muscle contraction and gland secretion. Specifically, its action on the M3 receptors in the gut wall leads to a reduction in the tone and amplitude of contractions in the stomach and intestines. Its action on the M1 receptors in the stomach lining results in a decrease in the production of gastric acid and pepsin.
The onset of action for clidinium is typically within 1 hour of oral administration. The duration of the antispasmodic effect lasts approximately 3 to 6 hours, which is why it is dosed multiple times per day. Patients usually notice a reduction in cramping and bloating within the first few days of therapy. Tolerance to the antispasmodic effects is rare, but patients may become 'used' to the side effects like dry mouth over time.
| Parameter | Value |
|---|---|
| Bioavailability | ~10-20% (Low/Variable) |
| Protein Binding | Moderate |
| Half-life | 2 to 4 hours (Clidinium component) |
| Tmax | 1 to 2 hours |
| Metabolism | Hepatic (Minimal CYP involvement) |
| Excretion | Renal (Primary), Fecal (Secondary) |
Clidinium is classified as a Gastrointestinal Anticholinergic/Antispasmodic. It is related to other medications like dicyclomine (Bentyl) and hyoscyamine (Levsin), although those are tertiary amines that cross into the brain more readily than clidinium. Within the broader therapeutic area, it is considered an 'adjunct' treatment for acid-peptic disorders and functional bowel syndromes.
Common questions about Clidinium
Clidinium is primarily used as an adjunctive treatment for gastrointestinal disorders such as peptic ulcers, irritable bowel syndrome (IBS), and acute enterocolitis. It works by slowing the movement of the intestines and reducing the production of stomach acid, which helps to relieve symptoms like stomach cramps, spasms, and abdominal pain. It is most commonly found in a combination pill that also contains a mild sedative to help with the anxiety often associated with gut issues. Your doctor may prescribe it when other treatments for these conditions have not provided sufficient relief. It is important to remember that it treats the symptoms of these conditions rather than curing the underlying cause.
The most common side effects of clidinium are related to its anticholinergic activity, which 'dries out' various bodily functions. Patients frequently report dry mouth, blurred vision, and constipation as the primary issues. Some individuals may also experience a decrease in sweating, which can lead to overheating, or a slight increase in heart rate. Drowsiness is also very common, especially if you are taking the version that is combined with a sedative. Most of these side effects are dose-dependent, meaning they may improve if your doctor adjusts your dosage. Always report persistent or bothersome side effects to your healthcare provider.
No, you should strictly avoid alcohol while taking clidinium, particularly if you are taking the common combination form that includes chlordiazepoxide. Alcohol is a central nervous system depressant that can dangerously increase the sedative effects of the medication, leading to extreme dizziness, confusion, and impaired coordination. Furthermore, mixing alcohol with the sedative component of this medication can lead to respiratory depression, which is a life-threatening condition where breathing becomes too slow or shallow. Alcohol can also irritate the stomach lining, potentially worsening the very gastrointestinal conditions clidinium is meant to treat. Discuss your alcohol consumption honestly with your doctor before starting this medication.
Clidinium is generally not recommended during pregnancy, especially during the first trimester. It is often combined with chlordiazepoxide, which has been linked to an increased risk of birth defects like cleft lip or palate when used early in pregnancy. While clidinium itself is in Pregnancy Category C, the combination product is often considered Category D, meaning there is evidence of human fetal risk. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits of this medication with your doctor. They will likely suggest safer alternatives for managing your gastrointestinal symptoms during this time.
Clidinium begins to work relatively quickly, with most patients feeling the initial effects within 1 to 2 hours after taking a dose. However, for chronic conditions like irritable bowel syndrome or peptic ulcers, it may take several days of consistent use to see a significant improvement in overall symptoms. Because it is often taken before meals, you should notice a reduction in the spasms and pain that usually follow eating fairly soon after starting the regimen. If you do not feel any improvement after a week of regular use, contact your doctor to discuss whether a dose adjustment or a different medication is necessary.
You should not stop taking clidinium suddenly, especially if you have been using it for more than a few weeks. This is particularly important for the combination version containing chlordiazepoxide, as your body can develop a physical dependence on the sedative component. Abruptly stopping can lead to withdrawal symptoms such as tremors, sweating, muscle cramps, anxiety, and in severe cases, seizures. Even with clidinium alone, stopping suddenly might cause a 'rebound' of your gastrointestinal symptoms. Your healthcare provider will provide a schedule to gradually taper your dose down to ensure your body adjusts safely.
If you miss a dose of clidinium, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed one and continue with your regular timing. It is important never to take two doses at once to make up for a missed one, as this can lead to an overdose and severe side effects like blurred vision or an inability to urinate. To help you remember your doses, try taking them at the same time every day, such as 30 minutes before your main meals. If you find yourself frequently missing doses, talk to your pharmacist about using a pill organizer or a reminder app.
Weight gain is not a commonly reported side effect of clidinium bromide. However, because the medication is used to treat painful gastrointestinal conditions, some patients may find that they can eat more comfortably once their symptoms are under control, which could lead to secondary weight gain. Additionally, the sedative component in the combination product can sometimes lead to increased appetite or reduced physical activity in some individuals. If you notice significant or rapid changes in your weight while taking this medication, discuss them with your doctor to rule out other causes. Maintaining a balanced diet and regular exercise is always recommended.
Clidinium can interact with many other medications, so it is vital to provide your doctor with a complete list of everything you take, including over-the-counter drugs and supplements. It should not be taken with certain potassium supplements or other drugs that slow down the gut, like pramlintide. Combining it with other anticholinergics (like certain allergy meds or antidepressants) can lead to severe 'drying' side effects and confusion. If you are taking the combination form, you must also be very careful with other sedatives or opioid pain medications. Your pharmacist can check for specific drug interactions every time you start a new prescription.
Yes, clidinium bromide is available as a generic medication, but it is almost always sold as a generic version of the combination product (Clidinium Bromide and Chlordiazepoxide Hydrochloride). Generic versions are typically more cost-effective than brand-name versions like Librax and contain the same active ingredients in the same strengths. When you fill your prescription, your pharmacist will usually provide the generic version unless your doctor specifically requests the brand name. Both the generic and brand-name versions are subject to the same strict FDA quality standards for safety and effectiveness.